Latest News

Add to Favorites Subscribe Share
newswise-fb-share-

Showing results

110 of 270
Wis_Square_logo_color.png

Article ID: 712927

Enhanced Anticancer Compound May Allow for Precise Activation and Tracking of Treatment

Wistar Institute

Wistar and the University of South Florida researchers have advanced a novel compound that specifically targets the endoplasmic reticulum (ER) stress response that is frequently hyperactivated in cancer and promotes survival of cancer cells during stressful conditions.

Released:
15-May-2019 12:05 PM EDT
Open in New Tab
Comment
Wistar_night.jpg

Article ID: 711760

Wistar Earns ‘Exceptional’ Rating for NCI Cancer Center Support Grant for the Second Review Cycle in a Row, Demonstrating Strength of Science

Wistar Institute

The Wistar Institute’s Cancer Center has received an “exceptional” rating on its Cancer Center Support Grant (CCSG) application from the National Cancer Institute (NCI) for the second review cycle in a row and the grant has been recommended for renewal, providing $13.6 million to the Cancer Center scientific enterprise.

Released:
23-Apr-2019 10:00 AM EDT
Open in New Tab
Comment

Channels:

English, Cancer

Wis_Square_logo_color.png

Article ID: 710850

Synthetic DNA-encoded Antibodies Against Zika Virus Shown to be Effective in Preclinical Studies

Wistar Institute

New approach for delivery of DNA-encoded monoclonal antibodies (DMAbs) has been reported by Wistar scientists. This new technology allows direct production of monoclonal antibody-like molecules in living animals.

Released:
5-Apr-2019 11:05 AM EDT
Open in New Tab
Comment
Wis_Square_logo_color.png
  • Embargo expired:
    6-Mar-2019 2:00 PM EST

Article ID: 709100

New Small Molecule Inhibitors Show Potential for Treatment of Epstein-Barr Virus-Associated Cancers

Wistar Institute

Researchers at The Wistar Institute have created a drug candidate for cancers associated with Epstein-Barr Virus (EBV), the virus that causes infectious mononucleosis.

Released:
5-Mar-2019 10:40 AM EST
Open in New Tab
Comment
Wis_Square_logo_color.png
  • Embargo expired:
    18-Feb-2019 11:00 AM EST

Article ID: 708218

New Insight Into the Balance Between the Tumor-suppressive and Tumor-promoting Effects of Cellular Senescence

Wistar Institute

Researchers at The Wistar Institute have described a novel role of nicotinamide adenine dinucleotide (NAD+) metabolism in the ability of senescent cells to release tumor-promoting molecules.

Released:
18-Feb-2019 11:00 AM EST
Open in New Tab
Comment
Wis_Square_logo_color.png

Article ID: 708100

Combination of T Cell Therapy and Targeted Therapy as a Novel Strategy for Therapy-resistant Melanoma with Mutations in the BRAF Gene

Wistar Institute

Collaborative research by The Wistar Institute and Moffitt Cancer Center has demonstrated that BRAF targeted therapies render resistant melanoma more sensitive to the attack of killer T cells.

Released:
14-Feb-2019 10:00 AM EST
Open in New Tab
Comment
Wis_Square_logo_color.png

Article ID: 707853

Federal Funding Fueled Growth of Wistar Science in 2018

Wistar Institute

The Wistar Institute announces that it was awarded more than $16M in federal research funds in support of its groundbreaking research in cancer, immunology and infectious diseases.

Released:
11-Feb-2019 11:00 AM EST
Open in New Tab
Comment
Wis_Square_logo_color.png
  • Embargo expired:
    7-Feb-2019 2:00 PM EST

Article ID: 707587

Engineered DNA Vaccine Protects Against Emerging Mayaro Virus Infection

Wistar Institute

A novel, synthetic DNA vaccine developed at The Wistar Institute induces protective immunity against Mayaro virus (MAYV), a mosquito-borne infection endemic to South America, that has the potential to become a global emerging viral threat.

Released:
5-Feb-2019 4:10 PM EST
Open in New Tab
Comment
Wis_Square_logo_color.png
  • Embargo expired:
    24-Jan-2019 10:00 AM EST

Article ID: 706892

Induction of Potent Anticancer Immunity Through Rapid Tumor Antigen Identification and Conversion to Personalized Synthetic DNA Vaccines

Wistar Institute

Wistar scientists and collaborators demonstrated the utility of an optimized synthetic DNA vaccine platform for rapidly inducing immunity against unique combinations of tumor neoantigens.

Released:
22-Jan-2019 4:30 PM EST
Open in New Tab
Comment
newZika_shutterstock_2meg.jpg

Article ID: 706159

First-in-Class DNA-encoded Monoclonal Antibody Therapy Rapidly Advances into the Clinic

Wistar Institute

Wistar, along with partners Penn Medicine and Inovio Pharmaceuticals, Inc. announce the FDA has approved the initiation of a first-in-human clinical trial investigating safety and tolerability of a novel synthetic DNA-encoded monoclonal antibody (DMAb) therapeutic technology for the prevention of Zika virus infection.

Released:
8-Jan-2019 2:05 PM EST
Open in New Tab
Comment

Showing results

110 of 270

Chat now!